Notice of Annual Meeting of Shareholders 2020

Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or the Company) will be held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand, on Wednesday, 12 August 2020 commencing at 10.30am (New Zealand time).

Agenda

  • Addresses

Our Chair, David Flacks, and our Founder and Chief Executive Officer, Hartley Atkinson, will provide an overview of the Company’s performance for the year ended 31 March 2020. There will also be an opportunity for shareholders to ask questions.

  • Resolutions

Shareholders will be asked to consider, and if thought fit, pass the following ordinary resolutions:

1. That the directors are authorised to fix the fees and expenses of Deloitte as auditor for the 2021 financial year.

2. That Ms Marree Atkinson be re-elected as a director of AFT Pharmaceuticals Limited.

Resolutions 1 and 2 are ordinary resolutions and must be approved by a simple majority of the votes of those shareholders entitled to vote and voting on the resolutions.

See explanatory notes on each of these resolutions below. No shareholder is restricted from voting on resolutions 1 and 2.

The Board recommends unanimously that you vote in favour of all resolutions.

  • General Business

To consider any other matter that may be brought properly before the Annual Meeting.

By Order of the AFT Pharmaceuticals Limited Board

David Flacks

Chairman

15th July 2020

Explanatory Notes:

Resolution 1: Auditor’s Remuneration

Deloitte is automatically reappointed auditor of the Company at the Annual Meeting pursuant to the Companies Act 1993. The resolution sought is to authorise the directors to fix the remuneration of the auditor pursuant to section 207(S)(a) of the Companies Act 1993.

Resolution 2: Re-election of Ms Marree Atkinson as a Director

Marree was appointed as a director by the shareholders of AFT on 4 September 2012, and was last re-elected in 2017. In accordance with the applicable NZX listing rules, Marree retires by rotation and offers herself for re-election as a director of AFT at the meeting. The Board unanimously supports Marree’s re-election and considers Marree to be a non-independent director.

Marree Atkinson Executive Director

Marree has been involved in all aspects of AFT’s business since its establishment in 1997, including roles in sales, regulatory affairs, customer services and logistics. Marree’s role as Chief of Staff sees her involved in the day-to-day running of AFT’s head office including managing staffing requirements and special projects involving AFT’s head and affiliate offices. Marree is a registered nurse previously practising at Waikato Hospital.

Important Information:

Attendance of Meeting

All shareholders registered on the Company’s share register at the date of the meeting are entitled to attend and vote at the meeting.

Voting and Proxies

Voting at the meeting shall be by way of a poll of the Company’s shareholders entitled to vote and voting.

A shareholder entitled to attend and vote at the meeting can appoint a proxy to attend and vote on their behalf. A proxy need not be a shareholder. The Chair of the meeting may be appointed to act as proxy.

If the Chair of the meeting is appointed to act as proxy and is not directed how to vote, the Chair will vote in favour of all the resolutions.

If you do not name a person as your proxy or your named proxy does not attend the meeting, the Chairman will be appointed your proxy and may only vote in accordance with your express direction.

A shareholder wishing to appoint a proxy can do so by visiting www.investorvote.co.nz. Holders will be required to enter their CSN/Holder Number and postcode or country of residence to complete the online appointment.

Alternatively, shareholders can appoint a proxy by completing the enclosed proxy form and returning it to Computershare Investor Services Limited by any of the methods specified on the proxy form.

The proxy form must be received no later than 10.30am on Monday 10 August 2020 (being 48 hours prior to the meeting).

Webcast

The Annual Meeting will be webcast live. To view and listen to the webcast, please visit https://www.openbriefing.com/OB/3821.aspx.

Note that shareholders joining by webcast will not be able to vote at the meeting or ask questions. In order to vote you will need to appoint a proxy in accordance with the above instructions   before    10.30am    on    Monday 10 August 2020.

If you have any questions you would like considered at the meeting, please send them to investor.relations@aftpharm.com in advance of the meeting.

More Information

If you have any questions, or for more information, please contact AFT’s Company Secretary, at investor.relations@aftpharm.com

May 1, 2024

AFT Licenses Maxigesic® IV in Brazil

We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazi…

Read More

April 24, 2024

AFT, Massey Ventures, Gilles McIndoe to develop scar treatment

AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….

Read More

March 5, 2024

AFT makes further progress in international markets

AFT Pharmaceuticals provides an update on recent progress it has made in international markets….

Read More